分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Hepatokine ORM2 suppresses pathological ferritinophagy to prevent acute tissue injury

Tang Hongyi, Wang Shu, Liu Fang, Shen Boqian, Jiang Feng, Xiong Xinyuan, Yang Nan, Zhu Huiqin, Zhang Rulin, Xia Dongge, Cong Cong, Lu Yan, Yang Jie, Wu Jun, Zhou Bing, Sun Xuxu

Journal:Cell Death & Disease

IF:12.2

DOI:10.1038/s41419-026-08803-0

PMID:

Published:2026-04-30

research field:细胞生物学铁代谢肝脏病学治疗学分子医学

Abstract

Acute tissue injuries trigger rapid cellular damage, but cell-intrinsic protective programs attenuate pathology through regulatory axes. Here, we demonstrate that Orosomucoid 2 (ORM2), a hepatokine, is significantly upregulated during drug-induced acute liver injury. Knock out Orm2 exacerbates liver damage, while its overexpression provides protection, identifying ORM2 as an endogenous hepatoprotective factor during acute liver injury. Mechanistically, ORM2 disrupts the FTH-NCOA4-TAX1BP1 interaction, thereby blocking ferritinophagy and preventing iron overload-induced cytotoxicity. Furthermore, acute ischemia-reperfusion injuries in other organs also trigger hepatic ORM2 upregulation and secretion, demonstrating liver-organ crosstalk via the circulatory system. Exogenous administration of ORM2 effectively ameliorates ferroptosis and tissue damage in multiple ischemia-reperfusion injury models. Collectively, our results identify the hepatokine ORM2 as a key suppressor of pathological ferritinophagy. This function positions ORM2 protein as a potential therapeutic candidate for acute tissue injuries driven by ferritinophagy-mediated iron overload.

本文使用的Yeasen产品

购物车
客服
转染试用